Want to find out if you've got ovarian cancer? Then Aspira Women's Health's OvaWatch could be for you.
The Intercept reports OvaWatch is an AI-based blood test for ovarian cancer that's currently in clinical trials.
It's one of a number of new tests Aspira is developing for conditions such as endometriosis, which is caused by abnormal tissue growth in the uterus.
Aspira CEO Nicole Sandford says ovarian cancer is a "huge, huge market" and OvaWatch is expected to be a "game-changer" in women's health.
The test is based on a protein-based blood test that's been shown to detect ovarian cancer, according to a press release.
Aspira is also developing an AI-based endometriosis test called EndoMDX.
It's currently in the final stages of design for a microRNA signature to identify endometriosis and expects to complete verification in 2024, Sandford says.
Aspira reported Q4 revenue of $2.1 million, flat with Q4 2022 but up 15% year-over-year.
For the full year, revenue was $9.2 million, up 15%.
The company reported a 49% drop in cash used in 2023 to $9.15 million, according to InvestingPro.
Read the Entire Article
A customized collection of news from foundations from around the Web.
TheĀ Festival of Inclusive Arts, organized by theĀ Arts with the Disabled Association, gives disabled performers a chance to shine.